表紙
市場調査レポート

筋萎縮性側索硬化症 (ALS) :主要9市場の予測 (2016年〜2026年)

Amyotrophic Lateral Sclerosis in 9 Major Markets 2016-2026

発行 Black Swan Analysis 商品コード 353578
出版日 ページ情報 英文 41 Pages
即納可能
価格
本日の銀行送金レート: 1USD=101.50円で換算しております。
Back to Top
筋萎縮性側索硬化症 (ALS) :主要9市場の予測 (2016年〜2026年) Amyotrophic Lateral Sclerosis in 9 Major Markets 2016-2026
出版日: 2016年03月07日 ページ情報: 英文 41 Pages
概要

当レポートでは、主要9市場 (米国、フランス、ドイツ、イタリア、スペイン、英国、ブラジル、日本、インド) における筋萎縮性側索硬化症 (ALS) の現在の患者数 (性別、年齢コホート別) について調査分析し、現在の有病率のほか、疾患の概要、危険因子、疾患の診断と予後、主な症状や合併症など、体系的な情報を提供しています。

図表

イントロダクション

病因

危険因子と予防

疾患の診断

変異:地域/民族別

疾患予後と臨床経過

疾患に関連する主な合併症/特徴

患者数を定量化する手法

筋萎縮性側索硬化症 (ALS) の有病率トップライン

筋萎縮性側索硬化症 (ALS) 患者の主な合併症・特徴

  • ALSの原因
  • 弧発性ALS患者の主な特徴・合併症
  • 延髄発症のあるALS患者

略語

関連出版

患者ベースのオンラインデータベース

患者ベースの製品

価格のオンラインデータ・プラットフォーム

参考文献

付録

目次
Product Code: AMLS0010316

Amyotrophic lateral sclerosis (ALS), also called Lou Gehrig's disease or motor neuron disease, is a is a rapidly progressive, fatal neurological disease in which upper and lower motor neurons degrade and eventually die. As motor function decreases, muscles weaken and waste; eventually the brain is no longer able to control autonomic functions such as breathing and heart rate.

This report provides the current prevalent population for ALS across 9 Major Markets (USA, France, Germany, Italy, Spain, UK, Brazil, Japan and India) split by gender and 5-year age cohort. Along with the current prevalence, the report also contains a disease overview of the risk factors, disease diagnosis and prognosis along with specific variations by geography and ethnicity.

Providing a value-added level of insight from the analysis team at Black Swan, several of the main symptoms and co-morbidities of ALS have been quantified and presented alongside the overall prevalence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.

Main symptoms and co-morbidities for ALS include:

  • Loss of speech
  • Depression
  • Dysphagia
  • Tongue twitch
  • Dementia (e.g. Frontotemporal lobe dementia)
  • Mild cognitive impairment
  • Breathing difficulties (e.g. dyspnoea)
  • Respiratory failure

This report is built using data and information sourced from the proprietary Epiomic patient segmentation database. To generate accurate patient population estimates, the Epiomic database utilises a combination of several world class sources that deliver the most up to date information from patient registries, clinical trials and epidemiology studies. All of the sources used to generate the data and analysis have been identified in the report.

Reason to buy

  • Able to quantify patient populations in the global ALS market to target the development of future products, pricing strategies and launch plans.
  • Gain further insight into the prevalence of the subdivided types of ALS and identify patient segments with high potential.
  • Delivery of more accurate information for clinical trials in study sizing and realistic patient recruitment for various countries.
  • Provide a level of understanding on the impact from specific co-morbid conditions on ALS's prevalent population.
  • Identify sub-populations within ALS which require treatment.
  • Gain an understanding of the specific markets that have the largest number of ALS patients.

Coverage

  • US
  • UK
  • FR
  • DE
  • IT
  • ES
  • JP
  • BR
  • IN

Table of Contents

  • List of Tables and Figures
  • Introduction
  • Cause of the Disease
  • Risk Factors & Prevention
  • Diagnosis of the Disease
  • Variation by Geography/Ethnicity
  • Disease Prognosis & Clinical Course
  • Key Co-morbid Conditions/Features Associated with the Disease
  • Methodology for Quantification of Patient Numbers
  • Top-Line Prevalence for Amyotrophic Lateral Sclerosis
  • Features of ALS Patients
    • Origin of ALS
    • Sporadic ALS Patient Features and Comorbidities
    • ALS Patients with Bulbar Onset
  • Abbreviations used in the Report
  • Other Black Swan Analysis Publications
  • Black Swan Analysis Online Patient-Based Databases
  • Patient-Based Offering
  • Online Pricing Data and Platforms
  • References
  • Appendix

List of Tables

  • Prevalence of ALS, total (000s)
  • Prevalence of ALS, males (000s)
  • Prevalence of ALS, females (000s)
  • Origin of ALS presenting in patients, total (000s)
  • Clinical phenotype in ALS patients, total (000s)
  • Region of onset in GLOBAL phenotype ALS patients, total (000s)
  • Sporadic ALS patients with SOD1 mutation, total (000s)
  • Prevalence of mild cognitive impairment in sporadic ALS patients, total (000s)
  • Prevalence of dementia in sporadic ALS patients, total (000s)
  • Prevalence of dementia by type in sporadic ALS, total (000s)
  • Prevalence of loss of speech in bulbar onset ALS, total (000s)
  • Prevalence of dysphagia in bulbar onset ALS, total (000s)
  • Prevalence of tongue twitch in bulbar onset ALS, total (000s)
  • Abbreviations and Acronyms used in the report
  • USA Prevalence of ALS by 5-yr age cohort, males (000s)
  • USA Prevalence of ALS by 5-yr age cohort, females (000s)
  • France Prevalence of ALS by 5-yr age cohort, males (000s)
  • France Prevalence of ALS by 5-yr age cohort, females (000s)
  • Germany Prevalence of ALS by 5-yr age cohort, males (000s)
  • Germany Prevalence of ALS by 5-yr age cohort, females (000s)
  • Italy Prevalence of ALS by 5-yr age cohort, males (000s)
  • Italy Prevalence of ALS by 5-yr age cohort, females (000s)
  • Spain Prevalence of ALS by 5-yr age cohort, males (000s)
  • Spain Prevalence of ALS by 5-yr age cohort, females (000s)
  • United Kingdom Prevalence of ALS by 5-yr age cohort, males (000s)
  • United Kingdom Prevalence of ALS by 5-yr age cohort, females (000s)
  • Brazil Prevalence of ALS by 5-yr age cohort, males (000s)
  • Brazil Prevalence of ALS by 5-yr age cohort, females (000s)
  • Japan Prevalence of ALS by 5-yr age cohort, males (000s)
  • Japan Prevalence of ALS by 5-yr age cohort, females (000s)
  • India Prevalence of ALS by 5-yr age cohort, males (000s)
  • India Prevalence of ALS by 5-yr age cohort, females (000s)
Back to Top